Eva Romanovsky

Jun 12, 2024 | nature.com | Jan Budczies |Eva Romanovsky |Olaf Neumann |Thorsten Stiewe |Daniel Kazdal |Petros Christopoulos

AbstractPredictive biomarkers in use for immunotherapy in advanced non-small cell lung cancer are of limited sensitivity and specificity. We analysed the potential of activating KRAS and pathogenic TP53 mutations to provide additional predictive information. The study cohort included 713 consecutive immunotherapy patients with advanced lung adenocarcinomas, negative for actionable genetic alterations.